TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. TRACON Pharmaceuticals, Inc. is not a good value stock. TRACON Pharmaceuticals, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in TRACON Pharmaceuticals, Inc..
Log in to see more information.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies...
TCON Fundamental Data by TradingView

News

Tracon Pharmaceuticals just downgraded at H.C. Wainwright, here's why
Tracon Pharmaceuticals just downgraded at H.C. Wainwright, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform

Globe Newswire The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary...\n more…

TRACON Pharmaceuticals Announces Executive Officer Resignation
TRACON Pharmaceuticals Announces Executive Officer Resignation

TipRanks Financial Blog TRACON Pharmaceuticals (TCON) just unveiled an update. David Lazar stepped down as Chief Business Development Officer of his company on June 19, 2024, on his own ac...\n more…

Tracon Pharmaceuticals announces publication of Phae 2 data for TRC102
Tracon Pharmaceuticals announces publication of Phae 2 data for TRC102

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

Globe Newswire Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam...\n more…

TCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024
TCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nTCON stock results show that TRACON Pharma missed analyst estimates for earnings per share the first quarter of 2024.\nThe post TCON...\n more…